Olga L. Bockeria

  • Citations Per Year
Learn More
Heart failure is one of the key causes of morbidity and mortality world-wide. The recent findings that regeneration is possible in the heart have made stem cell therapeutics the Holy Grail of modern cardiovascular medicine. The success of cardiac regenerative therapies hinges on the combination of an effective allogeneic “off the shelf” cell product with a(More)
BACKGROUND Most drug-eluting stent (DES) trials have excluded patients with chronic kidney disease (CKD). The efficacy of DES implantation in patients with CKD is therefore not known. OBJECTIVES To evaluate the outcomes with DES vs bare-metal stent (BMS) implantation in patients with CKD. METHODS AND RESULTS MEDLINE, EMBASE, and CENTRAL were searched(More)
AIM To estimate whether optimal antiplatelet therapy can be selected in terms of CYP2C19 polymorphism. SUBJECTS AND METHODS The prospective randomized trial included 124 patients (93 men and 31 women) who were to undergo percutaneous coronary intervention. They initially received dual antiplatelet therapy: clopidogrel 75 mg + acetylsalicylic acid (ASA)(More)
Heart failure risk factors research as well as studies of myocardial dysfunction to identify subclinical heart disease are important problems that can be solved with stress echocardiography and new methods of myocardial function analysis. Key factors defining the prognosis of patients with valvular diseases are heart remodeling and myocardial contractility.(More)
H istrical Pges LV systolic function, heavily compromised at presentation, improves rapidly in a period of days to weeks w1, 5–7x. Reports of Takotsubo syndrome after open cardiac surgery are few. It is possible that some cases of transient LV sphericalization after mitral valve replacement surgery described previously to the recognition of this phenomenon(More)